Status:
COMPLETED
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
Lead Sponsor:
Eli Lilly and Company
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC
Eligibility Criteria
Inclusion
- histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)
- no prior chemotherapy
- WHO criteria for disease status assessment
Exclusion
- Concurrent administration of any other tumor therapy
- pregnant or breast feeding
- serious concomitant disorders
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00191841
Start Date
December 1 2002
End Date
February 1 2006
Last Update
July 24 2006
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Barnaul, Russia
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Moscow, Russia
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Saint Petersburg, Russia
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Ufa, Russia